Indivior (INDV) Expected to Announce Quarterly Earnings on Thursday

Indivior (NASDAQ:INDV) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $305.62 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Indivior Stock Down 2.8%

INDV opened at $32.93 on Tuesday. The company has a 50 day moving average of $34.73 and a two-hundred day moving average of $29.79. Indivior has a 52-week low of $7.62 and a 52-week high of $38.00. The company has a market cap of $4.12 billion, a P/E ratio of 35.79 and a beta of 0.80.

Insider Activity at Indivior

In related news, Director Keith Humphreys purchased 775 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director directly owned 5,802 shares of the company’s stock, valued at approximately $205,332.78. The trade was a 15.42% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Barbara Ryan acquired 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the acquisition, the director owned 1,963 shares in the company, valued at $69,470.57. This represents a 65.24% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 4,871 shares of company stock worth $172,385.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently bought and sold shares of INDV. Fuller & Thaler Asset Management Inc. grew its position in shares of Indivior by 101.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after acquiring an additional 3,201,639 shares in the last quarter. State Street Corp lifted its stake in Indivior by 65.5% during the fourth quarter. State Street Corp now owns 4,659,281 shares of the company’s stock worth $167,175,000 after purchasing an additional 1,844,532 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Indivior in the fourth quarter worth $61,208,000. Newtyn Management LLC increased its stake in Indivior by 61.1% during the third quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock valued at $101,262,000 after purchasing an additional 1,592,982 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Indivior during the third quarter valued at $33,496,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Analyst Ratings Changes

INDV has been the topic of several research reports. Craig Hallum reissued a “buy” rating and issued a $41.00 price objective on shares of Indivior in a research report on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating and set a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research report on Wednesday, January 28th. HC Wainwright upped their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, Piper Sandler reiterated an “overweight” rating and set a $41.00 price objective (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.